An international group of regulators and drug companies have agreed in principle to a framework that sets out eight steps for assessing a drug’s benefits and risks and could set the stage for a global approach to evaluating drugs.
The framework will not result in uniform decisions across countries, but rather will provide a structure for the benefit-risk assessment...